SCHEMBL6783902

SCHEMBL6783902

C/C(=C/C(=O)Nc1ccc(NC(=O)Nc2cccnc2)cc1C(=O)O)c1ccc2ccccc2c1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TERT O14746 5/20 0.62
NPC1 O15118 4/20 0.47
RAB9A P51151 3/20 0.47
ALDH1A1 P00352 2/20 0.47
HTT P42858 1/20 0.47
MEN1 O00255 5/20 0.45
KMT2A Q03164 5/20 0.45
MAPT P10636 3/20 0.45
LMNA P02545 1/20 0.45
ATM Q13315 1/20 0.45
GRIK1 P39086 1/20 0.45
IMPDH2 P12268 1/20 0.44
KDM4E B2RXH2 3/20 0.44
HSD17B10 Q99714 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.43
TP53 P04637 1/20 0.42
CYP1A2 P05177 1/20 0.42
CYP3A4 P08684 1/20 0.42
CYP2D6 P10635 1/20 0.42
CYP2C19 P33261 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6786594 0.91 TERT (0.72) TERTNPC1RAB9AMEN1KMT2A
SCHEMBL6791907 0.89 TERT (0.50) TERTNPC1RAB9AALDH1A1HTT
SCHEMBL6786810 0.86 TERT (0.71) TERTNPC1RAB9AKMT2AMAPT
SCHEMBL6781944 0.84 TERT (0.75) TERTNPC1RAB9AALDH1A1HTT
SCHEMBL6787594 0.84 TERT (0.63) TERTNPC1RAB9AALDH1A1MEN1
SCHEMBL6790433 0.84 TERT (0.66) TERTNPC1RAB9AMEN1KMT2A
SCHEMBL30714444 0.80 TERT (0.57) TERTNPC1RAB9AALDH1A1MEN1
SCHEMBL26922890 0.80 TERT (0.57) TERTNPC1RAB9AALDH1A1MEN1
SCHEMBL4024968 0.80 TERT (0.75) TERTNPC1RAB9AKDM4E
SCHEMBL6783765 0.80 TERT (0.59) TERTNPC1RAB9AALDH1A1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6727250-B2 ADMINISTERING COMPOUNDS SUCH AS TRANS-3-(NAPHTH-2-YL)-BUT-2-ENOIC ACID-N-(2-CARBOXY-PHENYL)-AMIDE OR LIKE FOR THERAPY OF CONDITIONS ASSOCIATED WITH INCREASED TELOMERASE ACTIVITY, E.G. TUMOUR DISEASES BOEHRINGER INGELHEIM PHARMA KG (DE) 2004-04-27 US disclosed
US-20020099089-A1 Carboxylic acid amides, pharmaceutical compositions containing these compounds, their use and preparation BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2002-07-25 US disclosed
US-6362210-B1 ANTITUMOR, ANTICANCER AGENT BOEHRINGER INGELHEIM PHARMA KG (DE) 2002-03-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020099089-A1 Carboxylic acid amides, pharmaceutical compositions containing these compounds, their use and preparation TERT, NAT1, POT1 TERT 1/4885NPC1 3387/4885RAB9A 2130/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.